152 related articles for article (PubMed ID: 36565894)
1. Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives.
Sirico M; Virga A; Conte B; Urbini M; Ulivi P; Gianni C; Merloni F; Palleschi M; Gasperoni M; Curcio A; Saha D; Buono G; Muñoz M; De Giorgi U; Schettini F
Crit Rev Oncol Hematol; 2023 Jan; 181():103900. PubMed ID: 36565894
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
Cantini L; Trapani D; Guidi L; Boscolo Bielo L; Scafetta R; Koziej M; Vidal L; Saini KS; Curigliano G
Cancer Treat Rev; 2024 Feb; 123():102669. PubMed ID: 38141462
[TBL] [Abstract][Full Text] [Related]
3. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi G; Carbognin L; Arcanà C; Parola S; Ventriglia A; Doronzo A; Garutti M; Orlandi A; Palazzo A; Fabi A; Bria E; Tortora G; Arpino G; Giuliano M; Del Mastro L; De Laurentiis M; Puglisi F
Cancer Treat Rev; 2022 Nov; 110():102454. PubMed ID: 35987149
[TBL] [Abstract][Full Text] [Related]
4. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.
Wang X; Fan Z; Wang X; He Y; Liu Y; Wang X; Zhang B; Jiang Z; Wang T; Yu Z; Wang F; Liu Y; Li Y; Zhang J; Luo B; Jiang H; Wang T; Xie Y; Li J; Ouyang T
Breast Cancer Res Treat; 2022 Oct; 195(3):301-310. PubMed ID: 35917052
[TBL] [Abstract][Full Text] [Related]
6. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
Torrisi R; Marrazzo E; Agostinetto E; De Sanctis R; Losurdo A; Masci G; Tinterri C; Santoro A
Crit Rev Oncol Hematol; 2021 Apr; 160():103280. PubMed ID: 33667658
[TBL] [Abstract][Full Text] [Related]
8. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
9. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
[TBL] [Abstract][Full Text] [Related]
11. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
13. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Yeo B; Dowsett M
Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
Madigan LI; Dinh P; Graham JD
Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.
Sella T; Kantor O; Weiss A; Partridge AH; Metzger O; King TA
Breast Cancer Res Treat; 2022 Aug; 194(3):663-672. PubMed ID: 35752703
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.
da Silva LR; de Andrade CA; Brenelli F; Ramalho S; Reinert T; de Souza ABA; da Silva AER; de Paula Leite Kraft MB; de Vasconcelos VCA; Frasson AL; Torresan RZ; Cabello C; Ellis MJ; Zeferino LC
Breast Cancer Res Treat; 2021 Apr; 186(3):753-760. PubMed ID: 33543355
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
19. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer.
Martínez-Pérez C; Turnbull AK; Kay C; Dixon JM
Expert Rev Anticancer Ther; 2023 Jan; 23(1):67-86. PubMed ID: 36633402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
